Radiation heart dose from MammoSite compared to IMRT for left-sided breast cancers

November 08, 2006

When compared to IMRT, MammoSite Brachytherapy does not always deliver lower doses of radiation to the heart during treatment of left sided breast cancers. That is the finding of a study presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.

MammoSite is a form of brachytherapy that uses a balloon catheter to deliver radiation. The balloon is surgically placed at the site where the tumor was removed and radiation is delivered through the catheter. IMRT, or intensity modulated radiation therapy, is a highly sophisticated system of delivering external-beam radiation that allows advanced planning for accuracy and reduced side effects.

"In theory, MammoSite brachytherapy has generally been associated with lower doses to the heart for left-sided breast cancers, but in our study, we found that IMRT in some patients confers less radiation to the heart when treating areas close to the chest wall," said Alice Tsai, M.D., a resident in the Radiation Oncology Department at Fox Chase Cancer Center.

MammoSite brachytherapy was simulated in 101 women with left sided breast tumors treated with IMRT. The maximum heart dose delivered by MammoSite was calculated and compared to the maximum heart doses delivered by IMRT. The patients were divided then into two separate groups. Group I consisted of patients with the higher heart doses from MammoSite simulations. Group II consisted of those with the higher heart doses from IMRT.

The researchers analyzed data to determine the minimum distance from the chest wall to place the MammoSite implant in order to reduce the dose of radiation to the heart, but a uniform distance could not be determined, but other important conclusions were made.

"Our study shows that MammoSite brachytherapy does not always confer a lower heart dose than IMRT in women with left sided breast tumors," concluded Tsai. "Care must be taken when assessing women who are candidates for MammoSite brachytherapy with thorough evaluation of CT scans to minimize heart toxicity when left breast tumors are close to the chest wall."
-end-
Fox Chase Cancer Center was founded in 1904 in Philadelphia as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Radiation Articles from Brightsurf:

Sheer protection from electromagnetic radiation
A printable ink that is both conductive and transparent can also block radio waves.

What membrane can do in dealing with radiation
USTC recently found that polymethylmethacrylate (PMMA) and polyvinyl chloride (PVC) can release acidic substance under γ radiation, whose amount is proportional to the radiation intensity.

First measurements of radiation levels on the moon
In the current issue (25 September) of the prestigious journal Science Advances, Chinese and German scientists report for the first time on time-resolved measurements of the radiation on the moon.

New biomaterial could shield against harmful radiation
Northwestern University researchers have synthesized a new form of melanin enriched with selenium.

A new way to monitor cancer radiation therapy doses
More than half of all cancer patients undergo radiation therapy and the dose is critical.

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
Oncotarget Volume 11, Issue 4: In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin - radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}.

Breaking up amino acids with radiation
A new experimental and theoretical study published in EPJ D has shown how the ions formed when electrons collide with one amino acid, glutamine, differ according to the energy of the colliding electrons.

Radiation breaks connections in the brain
One of the potentially life-altering side effects that patients experience after cranial radiotherapy for brain cancer is cognitive impairment.

Fragmenting ions and radiation sensitizers
The anti-cancer drug 5-fluorouracil (5FU) acts as a radiosensitizer: it is rapidly taken up into the DNA of cancer cells, making the cells more sensitive to radiotherapy.

'Seeing the light' behind radiation therapy
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime.

Read More: Radiation News and Radiation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.